Build my stack
Home · News · Hims & Hers peptide plans

Hims & Hers Says Its Peptide Offering Starts This Month, With BPC-157 and TB-500 to Follow 'When the Regulatory Environment Permits'

The short version

  • On its third-quarter earnings call on 9 November 2026, Hims & Hers said it expects to launch "the first phase of our peptide offering" later in November, with sermorelin, glutathione and NAD+. It calls the offering Peptides+ and says it will include clinician-led treatment plans and access to regular blood testing.
  • It plans to add BPC-157 and TB-500 "when the regulatory environment permits". Its chief executive said the company would make the raw active ingredients for those two at its own peptide facility in Menlo Park.
  • Its quarterly report to the SEC, filed the same day, says it bought a peptide manufacturing facility in February 2025, is subject to FDA rules as "an FDA-registered API manufacturer", and calls the regulatory framework for peptides "evolving and subject to change".
  • BPC-157 and TB-500 are two of the six peptides in the HHS enforcement discretion policy, which calls itself interim and says it is not binding. Public comments closed on 13 November.
  • Also on 9 November, the American Medical Association adopted policy urging HHS and the FDA to rescind policies that ease compounding of unapproved synthetic peptides. On 10 November five more states joined the FTC's lawsuit against Hims & Hers, a case about privacy, billing and cancellations, not peptides.

Hims & Hers, which sells prescription treatments to consumers through its websites and apps, says it will start offering peptides this month, and that BPC-157 and TB-500 will follow once regulators allow it. Its executives set out the plan on the company's third-quarter earnings call on 9 November 2026, and its quarterly report to the SEC, filed the same day, describes the manufacturing behind it. Here is what the company said and filed, what it is waiting for, and the pushback from doctors the same day, as of 12 November 2026.

Update, 14 November 2026: the HHS comment period closed on 13 November. As of 14 November HHS had published no final version of the policy and the docket held no new HHS document.

What Hims & Hers said

What was saidWhoWhere on the call
"Later this month, we expect to launch the first phase of our peptide offering that includes sermorelin, glutathione, and NAD+."Chief financial officerPrepared remarks
"We plan to add BPC-157 and TB-500 when the regulatory environment permits."Chief financial officerPrepared remarks
Peptides+ "will include clinician-led treatment plans and access to regular blood testing. We plan to follow with TB-500 and BPC-157 manufactured and compounded in the U.S."Chief executivePrepared remarks
The Peptides+ category is "going to be coming to market end of this month", with "things like glutathione, NAD, sermorelin, B-12"; a wait list was "launched quite recently"Chief executiveAnswer to an analyst
"Revenue contribution from our peptide offering is not expected to be material in the fourth quarter."Chief financial officerPrepared remarks

Source: Hims & Hers third-quarter 2026 earnings call, 9 November 2026, as transcribed by The Motley Fool (published 10 November, read 12 November 2026).

No prices and no exact launch date were given. The chief executive said the offering would come with a membership that "over time, incentivizes and allows for more whole life care". The company's earnings release of the same day, filed with the SEC, does not mention peptides.

Where the ingredients would come from

The quarterly report (Form 10-Q) says Hims & Hers acquired "a peptide manufacturing facility (and related assets)" in February 2025, "an operational area where we have not operated previously as an organization." As "an FDA-registered API manufacturer", it says, it is subject to FDA requirements, including the current good manufacturing practice rules for makers of active pharmaceutical ingredients, and to oversight by the California Department of Public Health as a registered drug manufacturer.

The filing also records $10.0 million paid in the first nine months of 2026 under "a one-time agreement with a company in the peptide manufacturing industry to obtain the expertise and technology necessary for us to independently manufacture certain peptide active pharmaceutical ingredients." Payments under it can reach $30.0 million, tied to milestones the company expects to reach within the next 12 months. The filing does not name the other company.

On the call, the chief executive said the facility is in Menlo Park. For TB-500 and BPC-157, where he said the supply chains for the raw ingredients are "not really at the quality that we'd like to see", the company would be "manufacturing raw APIs in our facilities in Menlo Park". He said that makes Hims & Hers "really the only company in the U.S. capable of having that degree of quality oversight for these therapies", a claim we have not verified.

What it is waiting for

BPC-157 and TB-500 are two of the six peptides in the enforcement discretion policy HHS published in the Federal Register on 30 October (91 FR 68526); the others are epitalon, KPV, MOTS-c and semax. HHS says it does not intend to take enforcement action against a State-licensed pharmacy, Federal facility or licensed physician that compounds a single-ingredient product from one of them when ten conditions are met. The notice calls the document a "draft" and says it "does not establish any rights for any person and is not binding on HHS or the public"; the policy calls itself an "interim policy". Our report on the published policy has the detail: what the HHS peptide policy says.

Asked on the call what else the company was looking for, the chief executive said: "I'll butcher the actual terminology. But essentially, right now, we're in a comment period where the FDA has put out the proposed ruling from HHS, and we expect in the next couple of weeks for those comments to be aggregated and then a perspective from FDA on the explicit rule-making to take place." He said decisions would follow on the "necessity of API testing" and on the tests and standards the FDA will expect. That timeline is his expectation. The notice says only that "FDA's future rulemakings may propose adding some or all of these peptides to the 503A bulks list based on the available evidence", and we found no published date for that.

The comment period on docket HHS-OASH-2026-0496 closed on 13 November at 11:59 pm Eastern (04:59 UTC on 14 November). On 14 November regulations.gov showed 115 posted comments and listed the docket as nonrulemaking, and HHS had published no final version of the policy.

Doctors pushed back the same day

Also on 9 November, at its Interim Meeting in Orlando, the American Medical Association's House of Delegates adopted policy on "unapproved synthetic peptides". The AMA says it will urge HHS, the FDA and other federal regulators "to immediately rescind administrative policies, or directives that ease restrictions on compounding and distributing synthetic peptides that lack FDA approval." It will also work with federal agencies, state medical boards and state boards of pharmacy to "pursue swift enforcement actions against compounding pharmacies, direct-to-consumer telehealth platforms, and online dispensaries distributing unapproved synthetic peptide formulations that lack FDA regulatory review." The release names neither Hims & Hers nor the HHS policy.

A separate case: the FTC lawsuit

On 10 November the Federal Trade Commission filed an amended complaint adding Arizona, Florida, Nebraska, Ohio and Wisconsin as co-plaintiffs in its lawsuit against Hims & Hers, first brought on 29 July with Utah and California (through Los Angeles County Counsel). The FTC alleges that the company shared consumers' sensitive health information with advertising platforms, including Meta and Snap, "despite claiming its services maintain consumers' privacy"; that it does not clearly disclose that it charges for prescriptions almost immediately after an intake form is submitted; and that it made subscriptions hard to cancel. The case is in the US District Court for the Northern District of California. The FTC files a complaint when it has "reason to believe" the law is being or is about to be broken, and, as its release says, "the case will be decided by the court."

In its 10-Q, Hims & Hers says it "believes it has meritorious arguments and intends to vigorously defend against the alleged claims". It moved to dismiss on 22 October, with a hearing set for 14 January 2027, and had recorded an accrual of approximately $60 million for the matter as of 30 September. The amended complaint is about data, billing and cancellations; it does not mention peptides.

What this changes, and what it does not

  • It is a company plan. Nothing said on the call changes the legal status of BPC-157 or TB-500. The HHS policy is interim, its comment period closed on 13 November with no final version published as of 14 November, and Hims & Hers itself says it is waiting for the regulatory environment to permit the two.
  • Prescription treatment, not research use. Hims & Hers describes clinician-led treatment with blood testing. Peptides sold for research use only are a separate market; the HHS policy mentions them once, as the practice it says it wants to discourage.
  • The rules are still moving. The company's own filing calls the regulatory framework for peptides "evolving and subject to change", and says changes "could restrict our ability to manufacture, supply, or offer peptide products".

This page is news on company, government and court records, not medical or investment advice. Peptide Bureau covers research peptides for laboratory research use only. For background on the compounds, see our guides to BPC-157 and TB-500, and to sermorelin side effects.

Questions readers ask

Does Hims & Hers sell BPC-157?

Not yet. On 9 November 2026 Hims & Hers said it plans to add BPC-157 and TB-500 "when the regulatory environment permits". The first phase of its Peptides+ offering, due later in November, includes sermorelin, glutathione and NAD+.

What is Hims & Hers Peptides+?

The company's peptide offering. On its 9 November call it said Peptides+ will include clinician-led treatment plans and access to regular blood testing, starting with sermorelin, glutathione and NAD+; the chief executive also named B-12. It will come with a membership. No prices were given.

When does Hims & Hers launch peptides?

Later in November 2026, the chief financial officer said on 9 November; the chief executive said "end of this month". No exact date was given, and the company said peptide revenue is not expected to be material in the fourth quarter.

Where would Hims & Hers get BPC-157 and TB-500?

The chief executive said the company would make the raw active ingredients at its peptide facility in Menlo Park. Its SEC filing says it acquired a peptide manufacturing facility in February 2025 and is subject to FDA rules as an FDA-registered API manufacturer.

What is Hims & Hers waiting for on BPC-157 and TB-500?

Regulators. HHS published an interim enforcement discretion policy covering BPC-157, TB-500 and four other peptides on 30 October 2026; it says it is not binding, and comments closed on 13 November. The chief executive said he expects FDA decisions to follow on testing and standards. See what the HHS peptide policy says.

Why is the FTC suing Hims & Hers?

The FTC, with Utah, California through Los Angeles County Counsel and, since 10 November, Arizona, Florida, Nebraska, Ohio and Wisconsin, alleges that Hims & Hers shared consumers' health information with advertising platforms despite privacy claims, did not clearly disclose when it charges for prescriptions, and made cancelling hard. Hims & Hers says it will defend itself; a hearing on its motion to dismiss is set for 14 January 2027. The case does not concern peptides.

Sources

  1. Hims & Hers Health, Inc.: Form 10-Q for the quarter ended 30 September 2026 (SEC EDGAR), filed 9 November 2026; read 12 November 2026
  2. Hims & Hers Health, Inc.: Form 8-K, exhibit 99.1, third quarter 2026 financial results (SEC EDGAR), 9 November 2026; read 12 November 2026
  3. The Motley Fool: Hims & Hers (HIMS) Q3 2026 earnings call transcript, call 9 November 2026; published 10 November 2026; read 12 November 2026
  4. American Medical Association: AMA adopts new policies to protect patients and strengthen public health, 9 November 2026; read 12 November 2026
  5. Federal Register: Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances (91 FR 68526, FR Doc. 2026-22192), published 30 October 2026; read 31 October 2026
  6. Regulations.gov: docket HHS-OASH-2026-0496, documents and posted comments, read 12 and 14 November 2026
  7. Federal Trade Commission: Five States Join FTC Lawsuit Alleging Hims and Hers Engaged in Deceptive and Unlawful Privacy Practices, 10 November 2026; read 12 November 2026
  8. FTC v. Hims & Hers Health, Inc., No. 3:26-cv-07871-VC (N.D. Cal.): first amended complaint (PDF), filed 10 November 2026; read 12 November 2026
  9. Federal Trade Commission: case page and timeline, Hims & Hers Health, Inc., FTC v., complaint 29 July 2026; page updated 10 November 2026; read 12 November 2026
How this piece was checked: every fact above was read on the source it links to on the day of publication, and anything we could not confirm on a dated primary document is either attributed to the outlet that reported it or left out. Corrections are made in place and dated. Research peptides discussed here are sold for research use only; nothing on this page is medical advice. See how the Bureau works and the enforcement tracker.